Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1963 Apr 13;1(5336):1001. doi: 10.1136/bmj.1.5336.1001

Parkinsonism Occurring with Methyldopa Treatment

Bernard M Groden
PMCID: PMC2122870  PMID: 13950624

Full text

PDF

Page 1001

1001

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AYD F. J., Jr A survey of drug-induced extrapyramidal reactions. JAMA. 1961 Mar 25;175:1054–1060. doi: 10.1001/jama.1961.03040120016004. [DOI] [PubMed] [Google Scholar]
  2. COSTA E., RINALDI F. Biochemical and electroencephalographic changes in the brain of rabbits injected with 5-hydroxytryptophan (influence of chlorpromazine premedication). Am J Physiol. 1958 Jul;194(1):214–220. doi: 10.1152/ajplegacy.1958.194.1.214. [DOI] [PubMed] [Google Scholar]
  3. COURVOISIER S., FOURNEL J., DUCROT R., KOLSKY M., KOETSCHET P. Propriétés pharmacodynamiques du chlorhydrate de chloro-3-(diméthylamino-3'-propyl)-10-phénothiazine (4,560 R.P.); étude expérimentale d'un nouveau corps utilisé dans l'anesthésie potentialisée et dans l'hibernation artificielle. Arch Int Pharmacodyn Ther. 1953 Jan;92(3-4):305–361. [PubMed] [Google Scholar]
  4. DALEY D., EVANS B. Another hypotensive agent--methyldopa. Br Med J. 1962 Jul 21;2(5298):156–158. doi: 10.1136/bmj.2.5298.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DOLLERY C. T., HARINGTON M. Methyldopa in hypertension. Clinical and pharmacological studies. Lancet. 1962 Apr 14;1(7233):759–763. doi: 10.1016/s0140-6736(62)91781-6. [DOI] [PubMed] [Google Scholar]
  6. GILLESPIE L., Jr Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine. Ann N Y Acad Sci. 1960 Oct 11;88:1011–1020. doi: 10.1111/j.1749-6632.1960.tb20092.x. [DOI] [PubMed] [Google Scholar]
  7. HARINGTON M. Pharmacology of hypotensive drugs. Br Med J. 1960 Mar 5;1(5174):717–719. doi: 10.1136/bmj.1.5174.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. OATES J. A., GILLESPIE L., UDENFRIEND S., SJOERDSMA A. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine. Science. 1960 Jun 24;131(3417):1890–1891. doi: 10.1126/science.131.3417.1890. [DOI] [PubMed] [Google Scholar]
  9. PAASONEN M. K., VOGT M. The effect of drugs on the amounts of substance P and 5-hydroxytryptamine in mammalian brain. J Physiol. 1956 Mar 28;131(3):617–626. doi: 10.1113/jphysiol.1956.sp005486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. PLETSCHER A., SHORE P. A., BRODIE B. B. Serotonin as a mediator of reserpine action in brain. J Pharmacol Exp Ther. 1956 Jan;116(1):84–89. [PubMed] [Google Scholar]
  11. REES L. Chlorpromazine and allied phenothiazine derivatives. Br Med J. 1960 Aug 13;2(5197):522–525. doi: 10.1136/bmj.2.5197.522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. SOURKES T. L. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine. Arch Biochem Biophys. 1954 Aug;51(2):444–456. doi: 10.1016/0003-9861(54)90500-7. [DOI] [PubMed] [Google Scholar]
  13. Weatherall M. Tranquillizers. Br Med J. 1962 May 5;1(5287):1219–1224. doi: 10.1136/bmj.1.5287.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES